Brokerages Set $15.00 Target Price for Sunshine Heart Inc (CHFS)

Sunshine Heart Inc (NASDAQ:CHFS) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price objective of $15.00 for the company, according to Zacks. Zacks has also given Sunshine Heart an industry rank of 168 out of 265 based on the ratings given to its competitors.

Several equities research analysts have recently issued reports on CHFS shares. Zacks Investment Research cut Sunshine Heart from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. ValuEngine upgraded Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 31st.

Shares of Sunshine Heart (NASDAQ:CHFS) traded up $0.03 during mid-day trading on Friday, hitting $3.20. The stock had a trading volume of 265,200 shares, compared to its average volume of 550,732. Sunshine Heart has a 1 year low of $2.87 and a 1 year high of $99.80. The company has a market capitalization of $5.70, a PE ratio of -0.02 and a beta of 2.34.

COPYRIGHT VIOLATION WARNING: “Brokerages Set $15.00 Target Price for Sunshine Heart Inc (CHFS)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/21/brokerages-set-15-00-target-price-for-sunshine-heart-inc-chfs.html.

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply